Peptonic Medical AB’s reconstruction plan approved by the Uppsala District Court
Idag, 15:00
Idag, 15:00
Peptonic Medical AB’s reconstruction plan approved by the Uppsala District Court
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has decided to approve the Company’s reconstruction plan. The court’s decision will become legally binding on 19 December 2025, unless the decision is appealed to the Svea Court of Appeal before that date.
The debt settlement in the reconstruction plan is conditional upon the share issues in the plan, and vice versa. If the share issues under the reconstruction plan are not completed by the last banking day of the month that falls two months after the reconstruction plan becomes legally binding, the reconstruction plan shall be considered void.
The minutes and decision are available on the Company’s website, peptonicmedical.se, under the Investors and Corporate Reconstruction sections.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB Email: anna.linton@peptonicmedical.se Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
Idag, 15:00
Peptonic Medical AB’s reconstruction plan approved by the Uppsala District Court
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has decided to approve the Company’s reconstruction plan. The court’s decision will become legally binding on 19 December 2025, unless the decision is appealed to the Svea Court of Appeal before that date.
The debt settlement in the reconstruction plan is conditional upon the share issues in the plan, and vice versa. If the share issues under the reconstruction plan are not completed by the last banking day of the month that falls two months after the reconstruction plan becomes legally binding, the reconstruction plan shall be considered void.
The minutes and decision are available on the Company’s website, peptonicmedical.se, under the Investors and Corporate Reconstruction sections.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB Email: anna.linton@peptonicmedical.se Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
BNP
Månadens mest köpta och sålda
Aktieråd
Saab
Analyser
ISK
BNP
Månadens mest köpta och sålda
Aktieråd
Saab
Analyser
ISK
1 DAG %
Senast

OMX Stockholm 30
1 DAG %
Senast
2 787,77